Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
milnacipran hcl | ANDA | 2024-07-30 |
savella | New Drug Application | 2025-03-04 |
savella savella | New Drug Application | 2017-12-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
major depressive disorder | EFO_0003761 | D003865 | F22 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Milnacipran Hydrochloride, Savella, Abbvie | |||
7994220 | 2029-09-19 | U-819 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
Drug common name | Milnacipran |
INN | milnacipran |
Description | (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide is a member of acetamides. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCN(CC)C(=O)C1(c2ccccc2)CC1CN |
PDB | — |
CAS-ID | 92623-85-3 |
RxCUI | — |
ChEMBL ID | CHEMBL259209 |
ChEBI ID | — |
PubChem CID | 65833 |
DrugBank | DB04896 |
UNII ID | G56VK1HF36 (ChemIDplus, GSRS) |